Navigation Links
Akorn, Inc. Announces Second Quarter 2009 Earnings Release and Conference Call Information
Date:7/29/2009

LAKE FOREST, Ill., July 29 /PRNewswire-FirstCall/ -- Akorn, Inc. (Nasdaq: AKRX) will release second quarter 2009 earnings Monday, August 10 after stock market close. The company will host a conference call on Tuesday, August 11 to discuss quarterly results followed by a Q&A session:

    Subject:               Akorn Second Quarter 2009 Conference Call

    Date/Time:             Tuesday, August 11, 2009 at 10:00 a.m. Eastern Time

    Domestic Callers:      (800) 289-0479

    International Callers: (913) 981-5519

URL For Webcast: http://www.videonewswire.com/event.asp?id=56168

The live broadcast of Akorn's conference call will also be available online at www.akorn.com under the investor relations tab on August 11, 2009, beginning at 10:00 a.m. (Eastern Time). The online replay will follow immediately and will be available for 30 days.

About Akorn, Inc.

Akorn, Inc. manufactures and markets sterile specialty pharmaceuticals. Akorn has manufacturing facilities located in Decatur, Illinois and Somerset, New Jersey and markets and distributes an extensive line of hospital and ophthalmic pharmaceuticals. Additional information is available at the Company's website at www.akorn.com.

This press release includes statements that may constitute "forward-looking statements", including with regard to the company's future operations and its earnings expectations. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with a discussion of future operating or financial performance. Factors that could cause or contribute to such differences include, but are not limited to: statements relating to future steps we may take, prospective products, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. These cautionary statements should be considered in connection with any subsequent written or oral forward-looking statements that may be made by the company or by persons acting on its behalf and in conjunction with its periodic SEC filings. You are advised, however, to consult any further disclosures we make on related subjects in our reports filed with the SEC. In particular, you should read the discussion in the section entitled "Cautionary Statement Regarding Forward-Looking Statements" in our most recent Annual Report on Form 10-K, as it may be updated in subsequent reports filed with the SEC. That discussion covers certain risks, uncertainties and possibly inaccurate assumptions that could cause our actual results to differ materially from expected and historical results. Other factors besides those listed there could also adversely affect our results


'/>"/>
SOURCE Akorn, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Stryker Announces Election of New Director
2. Birdies for Breast Cancer Announces Fifth Annual Charity Golf Classic Hosted by Top Womens Golfer, Cristie Kerr
3. ASTRO announces 2009 Fellows
4. Smith & Nephew Announces Launch of ACTICOAT Flex Wound Care Products in the USA
5. Boston Scientific Announces Election of Katharine Bartlett and Bruce Byrnes to Its Board of Directors
6. Hillenbrand Announces Third-Quarter Earnings Release Date and Conference Call
7. Access Pharmaceuticals Announces New MuGard Commercial Strategy in North America
8. Patriot Scientific Corporation Announces Cardiac Science Corporations Purchase of a Moore Microprocessor Patent(TM) Portfolio License
9. QuatRx Announces Further Positive Phase 3 Results For Ophena(TM) (Ospemifene Tablets) in Postmenopausal Vaginal Atrophy
10. Medivation Announces Second Quarter 2009 Financial Results Teleconference and Webcast on August 5, 2009
11. HCA Announces Offering of $750 Million Senior Secured First Lien Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2017)... , ... June 25, 2017 , ... CareSet Labs released ... in New Orleans. This is a new, greatly improved version of the Doctor Referral ... (FOIA) requests by Fred Trotter and subsequently called the the “Doctor Referral Dataset” as ...
(Date:6/25/2017)... ... June 25, 2017 , ... June is Men’s Health Month and the ... common cancer among men in the U.S. and the third most common cause of cancer ... that one man in seven will be diagnosed with prostate cancer during his lifetime. ...
(Date:6/24/2017)... (PRWEB) , ... June 24, 2017 , ... ... in Erie, PA at the Sheraton Erie Bayfront and Erie Convention Center on ... based medicine experience, exhibits, a student quiz bowl, award and scholarship presentations, and ...
(Date:6/24/2017)... ... June 24, 2017 , ... The weather is heating up and ... and business owners should be aware that the summer months provide more than warmer ... locks and keys can be negatively affected from direct exposure to the sun. When ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Rhode Island Quality ... Management Alerts and Dashboards, an innovative new service enabling healthcare providers to proactively ... Management Alerts and Dashboards provide near real-time data about patients admitted to and/or ...
Breaking Medicine News(10 mins):
(Date:6/3/2017)... June 3, 2017  Eli Lilly and Company ... results from the Phase 3 MONARCH 2 study ... 6 inhibitor, in combination with fulvestrant, significantly improved ... alone in women with hormone-receptor-positive (HR+), human epidermal ... who have relapsed or progressed after endocrine therapy ...
(Date:5/30/2017)... Corp. (NASDAQ: DRIO), a leading global digital health company with mobile ... presenting at the 7th annual LD Micro Invitational on Tuesday, June ... of DarioHealth will be giving the presentation and meeting with investors. ... 7th, 2017 at the Luxe Sunset Bel Air Hotel and will ... About LD Micro LD Micro was founded ...
(Date:5/29/2017)... TEL AVIV, Israel, May 29, 2017  Cellect Biotechnology ... of innovative technology which enables the functional selection of ... financial results for the first quarter ended March 31 ... pleased with our accomplishments in the first quarter of ... the first quarter, we announced the treatment of the ...
Breaking Medicine Technology: